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Abstract 
This study aimed to characterise three nasal drug delivery devices to evaluate their 
propensity to deliver human insulin solutions to the nasal cavity for redistribution to 
the central nervous system.  Brain delivery was evaluated using functional magnetic 
resonance imaging to measure regional cerebral blood flow.  Intranasal insulin 
administration has been hypothesised to exploit nose-to-brain pathways and deliver 
drug directly to the brain tissue whilst limiting systemic exposure.  Three nasal pump-
actuator configurations were compared for delivery of 400 IU/mL insulin solution by 
measuring droplet size distribution, plume geometry, spray pattern and in vitro 
deposition in a nasal cast.  The device with optimal spray properties for nose to brain 
delivery (spray angle between 30° and 45°; droplet size between 20 and 50 µm) also 
favoured high posterior-superior deposition in the nasal cast and was utilised in a 
pharmacological magnetic resonance imaging study.  Functional magnetic 
resonance imaging in healthy male volunteers showed statistically significant 
decreases in regional cerebral blood flow within areas dense in insulin receptors 
(bilateral amygdala) in response to intranasally administered insulin (160 IU) 
compared to saline (control).  These changes correspond to the expected effects of 
insulin in the brain and were achieved using a simple nasal spray device and 
solution formulation.  We recommend that a thorough characterisation of nasal 
delivery devices and qualitative/quantitative assessment of the administered dose is 
reported in all studies of nose to brain delivery so that responses can be evaluated 
with respect to posology and comparison between studies is facilitated.   
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1 Introduction 
Given the rising prevalence of diabetes mellitus and metabolic disorders, such as 
obesity, within the developed world [1] there has been an increase in the number of 
studies focused on the central nervous system response to insulin [2, 3].  The 
primary role of insulin in the body is to regulate and maintain normal blood glucose 
levels through cellular uptake and storage of glucose in skeletal and adipose tissue.  
In the brain, however, neuronal glucose uptake is insulin independent and insulin is 
involved with other processes within the brain which are mediated via the insulin 
receptor, i.e. homeostasis, food appetite regulation, food reward and memory [4, 5].  
Nasal administration has been proposed as a means to deliver insulin to the brain to 
study its effects with limited interference from systemic insulin-glucose interactions.  
Nose-to-brain delivery bypasses the blood brain barrier (BBB) by transport across 
olfactory epithelia into the subarachnoid space, effectively reaching brain tissue 
within 30-60 min [6].  Thus, nasal insulin administration can be utilised as a tool for 
research in patients with diabetes and obesity where regular receptor-mediated 
transport of insulin across the BBB to the brain tissue may be disrupted [7, 8]. 
 
For optimal nose-to-brain delivery, insulin must be deposited in the upper posterior 
region of the nasal cavity where the olfactory epithelium is located, Figure 1 [9, 10].  
To achieve optimal brain delivery sufficient drug solution must reach the olfactory 
epithelium deposition site (highlighted in Figure 1), which is situated proximally to the 
olfactory bulb and cribriform plate.  The olfactory receptor neurons, which are 
thought to provide a pathway for drug transport, are interspersed among supporting 
cells (sustentacular cells), microvillar cells, and basal cells [10].  Disappointingly, the 
dose-determining characteristics of delivery systems used to administer insulin in 
studies to date have not been well characterised or reported.  For example, minimal 
details regarding the nasal device, spray characteristics or deposition pattern are 
provided in a study demonstrating dose-dependent nose-to-brain insulin absorption 
[11].  Studies using both in vitro nasal casts and computational modelling provide a 
general framework of nasal pump performance characteristics that are optimal for 
posterior drug deposition which is necessary for efficient nose-to-brain drug delivery 
[12-14].  Critical performance parameters have been defined and underpin the 
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guidelines and regulations for nasal drug products of the regulatory agencies such 
as the FDA and EMA [15].  Nasal drug deposition is dependent on human factors 
such as actuation force, actuation angle and nasal anatomy as well as those dictated 
by the combination of device and formulation such as droplet size, plume angle and 
plume area.  The latter parameters can be measured using in vitro methods and 
serve as proxy measures for predicting spray distribution and deposition in the 
human nasal cavity.  Deposition studies in human cast models provide a simulation 
of nasal delivery to the human nasal cavity using a realistic anatomy and air flow.  
For upper nasal cavity drug deposition a device and formulation capable of 
producing a plume with a small spray angle (between 30° and 45°) and small 
droplets (between 20 and 50 µm) is desired [12-14].  
Locating drug-receptor binding in vivo can be conducted using imaging methods 
such as positron emission tomography, but comes at a large financial cost, requires 
complex chemistry and is inappropriate for repeated investigations due to radioactive 
isotope exposure.  Magnetic resonance imaging (MRI), on the other hand can be 
used for repeated measures as illustrated by several recently published 
pharmacological investigations [16].  An MRI method for pharmacological studies is 
arterial spin labelling (ASL), which permits measurement of cerebral blood flow 
(CBF) in quantitative units (ml/100 g/min) in a time of approximately 5-6 min [17]. 
Following changes in neuronal activity from a stimulus, such as a sensory or 
cognitive task or pharmacological modulation, the oxygen demand to the stimulated 
neuronal region is increased. This increase in oxygen is satisfied by an increase in 
blood flow to that region via vasodilation at the level of the arterioles through a 
phenomenon known as neurovascular coupling [18]. Therefore, changes in regional 
CBF (rCBF) which can be measured using ASL reflect changes in physiology that 
provide a surrogate measure of changes in neuronal activity. 
In this study we characterised the spray properties of human insulin solution in two 
commercially available nasal spray pumps with three types of actuator.  The nasal 
spray performance was evaluated using standard nasal drug product quality 
attributes [19].  These measurements were droplet size distribution, spray 
divergence angle/width and spray cross-sectional area/ovality.  Furthermore, nasal 
cavity deposition was compared using an in vitro nasal cast for each of the pump 
configurations look at how well the measured spray properties translated into 
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deposition patterns. The device with the characteristics that most favoured upper 
and posterior nasal cavity penetration was selected for an evaluation of nose-to-
brain delivery in human volunteers by using an MRI method, arterial spin labelling, to 
measure CBF as a functional biomarker for central insulin delivery.  In contrast to 
most nose-to-brain studies, we provide a detailed characterisation of the nasal 
delivery device and drug delivered to the nasal cavity. 
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2  Materials and Methods 
 
Human Insulin (Humulin®, 500 IU/ml) was purchased from Eli Lily, USA. Nasal spray 
pumps (100 µL) were provided by Nemera (La Verpillière, France), the SP270+® with 
two crimp-on actuator types (3959 and 4290) and a new prototype device with a 
single crimp-on nasal actuator (5701) (Figure 2A).  The SP270+ pump configurations 
and new prototype device were filled with 2.5 mL and 4.5 mL of insulin solution (400 
IU/mL; Humulin diluted 4:1 with saline 0.9% w/v immediately before administration - 
viscosity 0.967 ± 0.002 mPa.s at 25°C), respectively. 
 
2.1 Droplet Size Measurement 
Droplet size analysis was performed by laser diffraction using a Malvern Spraytec 
(Malvern Instruments, Inc, Southborough, MA) and Proveris Vero (Proveris  
Scientific Corporation, Malborough, MA) automated actuator for reliable and 
automated actuation of each pump configuration (n=5/pump).  Actuation force was 
kept constant for all experiments and pump configurations at 6.8 kg.  The automated 
actuator was placed between the laser and the detector lens at 90° to achieve 
vertical spray actuation. Data was collected at two distances from the tip of the 
actuator to the middle of the laser beam (30 mm and 60 mm) with single actuation 
per distance.  Data was processed and analysed using the Malvern software.  
Obscuration values over time were used to identify the stable phase when the plume 
is most constant, which was selected for analysis.  From this phase the particle size 
cut-offs encompassing 10, 50 and 90% of the total sample volume, the Dv10, Dv50 
and Dv90, as well as respirable fraction (% <10 µm) were estimated.  Unpaired t-
tests were performed between pump configurations to compare droplet size 
distributions. 
 
2.2 Plume Geometry and Spray Pattern Measurement 
A Proveris SprayView with Proveris Vero automated actuator (Proveris Scientific 
Corporation, Malborough, MA) and actuation settings as above were used to assess 
plume geometry and plume spray pattern.  The SprayView setup coupled a high-
speed camera and a pulsed laser light sheet to capture high quality images of the 
insulin plume as it evacuates the pump.  The laser light sheet orientation determines 
what information can be obtained.  For plume geometry, the light sheet was 
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positioned to dissect the centre of the plume from a single actuation, parallel to the 
plume flow. For spray pattern the light sheet was positioned to dissect the plume at 
an angle perpendicular to the flow of a single actuation with measurement at 
distances of 30 and 60 mm.  
 
For each test, using the Proveris software (Viota Software, Proveris Scientific 
Corporation, Malborough, MA), the image with maximal image intensity, i.e. plume at 
its largest, was used for analysis.  From this image the tip of the nozzle was located 
and the two arms of the left and right side of the plume were defined using a 
threshold selection process.  The angle between the two arms was measured as well 
as the distance between the two arms at a point 60 mm away from the tip of the 
nozzle, these metrics represent plume angle and width, respectively.  Using the 
Proveris software the total spray duration was manually defined using an image 
intensity graph, and the images selected were then used to analyse and calculate 
the area (mm2), defined as the area bounded by the spray pattern contours, as well 
as ovality.  Ovality is a ratio of the Dmax (the longest distance across the plume) and 
Dmin (the longest width across the plume).  Absolute ovality would give a value of 1, 
where Dmax=Dmin. 
 
2.3 Nasal Cast Deposition  
The nasal cast model (Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, 
Germany) used for these experiments was made from CT scan data of a complete 
adult human nose [20].  The cast consists of five parts representing nostrils, nasal 
vestibule, lower turbinates, middle and upper turbinates and nasopharynx (Fig 4a).  
At the end of the nasal cast a filter was used to collect the post-nasal fraction 
possibly reaching the lung.  The nasal cast was operated with inspiration flow of 15 
L/min generated by a vacuum pump connected to the filter holder at the rear end of 
the cast. The insulin solution (400 IU/mL) was administered to the cast using three 
nasal pump-actuator configurations.  Approximately 2.5 mL or 4 mL of insulin 
solution were filled into reservoir of the device and with each shot a single dose of 
100 µL was delivered from the device.  The nasal spray was inserted into the nostrils 
of the cast at an angle and penetration depth to mimic the administration procedure 
in the human volunteer study.  Two sprays into each nostril for each determination 
were delivered at an angle of 45° parallel to the septum.  As liquid sprays are not 
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susceptible to particle bounce the cast was not coated, but was dissembled 
immediately after administration of the sprays to minimise any opportunity for 
redistribution of the deposited dose.  Use of a concentrated insulin solution permitted 
administration of 400 µL spray which is less likely to result in run-off than higher 
volumes that are sometimes used, e.g. 1.6 mL [11].  Regional deposition was 
reproducible and no visible liquid pooling or signs of redistribution were observed. 
Individual cast segments were rinsed with 10 mL water to recover the insulin 
deposited in the nasal cast, which was measured by HPLC assay with all 
determinations performed in triplicate.   
 
A Waters 2796 Separations Module HPLC was used, equipped with Waters 2489 
Photodiode Array Detector.  The column was Thermo Scientific Hypersil 3 µm 
Hypurity Advance 150 × 4.6 mm RP8.  Data were digitalized by Empower program 
(Waters, Elstree, UK) for chromatograms and integration.  The column temperature 
was set at 25°C and the UV detection wavelength used at 214 nm.  An isocratic 
mobile phase consisting of phosphate buffered saline (PBS) and acetonitrile (70:30 
v/v), degassed was used in the HPLC analysis.  The flow rate of 1 mL/min and 
pressure limit of 1100 were set with injection volume of 100 µL.  Samples were 
analysed in duplicate with run time of 8 min.  The calibration curve was constructed 
by the standard insulin solution and it was used to quantify each sample peak 
obtained.  Stock solution of insulin (5 mg/mL) was prepared and serial dilutions 
(0.65, 1.25, 2.5, 5, 10, 20, 40, 80 µg/mL) were performed for construction of 
calibration curve.    
 
2.4 Human Volunteer Study 
2.4.1 Participants 
The device determined by in vitro studies to be most suitable for nose to brain 
delivery was selected for use in a double-blind randomised crossover fMRI study to 
investigate the effect of insulin on cerebral blood flow.  Here we report the data that 
provide evidence for delivery of insulin to the brain (changes in cerebral blood flow 
after administration of insulin compared to saline placebo) and systemic circulation 
(biochemical measures) following intranasal administration.  Sixteen healthy male 
volunteers were recruited (age= 24.67 ± 4.30, mean ± SD). All participants visited 
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three times in total, once for a screening session followed by two scanning visits 
separated by at least seven days.  All eligible participants had a body mass index 
(BMI) between 25-31.4 kg/m2 (BMI=27.76 ± 1.92), had no history of psychiatric 
illness or diabetes assessed by clinical interview, no cardiac complications as 
assessed by electrocardiogram (ECG), no history of any eating disorders, asthma or 
allergies associated with breathing difficulties and did not adhere to a vegetarian or 
vegan diet. All subjects were also screened for any MR contraindications.  This study 
was approved the King’s College London Psychiatry Nursing and Midwifery Ethics 
Committee (ethics no. RESCM-17/18-2282). 
On both scanning visits participants arrived following an overnight fast (approx. 12 
hours).  Blood samples were collected before and after scanning (pre dose and post 
scan) and were assessed for plasma glucose, serum insulin and serum C-peptide 
concentrations. 
 
2.4.2 Drug Administration 
Twenty minutes prior to being loaded into the scanner participants received either 
160 IU insulin (400 IU/mL) or saline solution 0.9% w/v (control)) via intranasal 
application using the SP270+ pump and 3959 actuator.  Administration was 
approximately thirty minutes prior to functional data acquisition in an effort to acquire 
data after insulin concentrations in the central nervous system had increased in 
accordance with the pharmacokinetics of intranasal insulin previously reported [21].  
 
Participants were familiarised with intranasal application and self-administered the 
dose under instruction from the lead investigator.  The nozzle was inserted into a 
nostril parallel to the septum at the same penetration depth and angle utilised for the 
nasal cast.  Participants received a total of 4 spray doses (i.e., 4 x 100 µL x 400 
IU/mL), alternating between nostrils and leaving one minute between each spray 
nostrils.  Participants took a forward leaning position and used their left hand to 
administer to the right nostril and vice versa.  Following each spray, participants 
were instructed to hang their head down and forward to prevent any drug loss to the 
nasopharynx nasal  and take advantage of gravitational forces to direct any transport 
towards the upper turbinates and olfactory regions of the nasal cavity.  
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2.4.3 MRI acquisition, Image Processing and Analysis 
All scanning was conducted using a MR750 3 Tesla GE Scanner with a 32 channel 
head coil.  High resolution anatomical images were acquired to permit spatial 
standardisation of functional data.  Resting cerebral perfusion images (functional 
data) were collected using a 3D pseudo-continuous arterial spin labelling (pCASL) 
sequence acquired at a resolution of 2.96 x 2.96 x 3 mm3 in a time of 5:22 min.  
During perfusion image acquisition participants were asked to keep their eyes open 
and look at a cross displayed to them on the screen. 
 
Quantitative maps of CBF were computed from perfusion weighted images using the 
scanner software, implementing the model recommended by the ASL White paper 
[22].  Anatomical images were used to create a group template using Advanced 
Normalistion Tools (ANTs, templatecreate.sh, [23]) which was registered to 
standardised space through FSL’s FLIRT [24, 25] (FSL, FMRIB, version 3.20, 
University of Oxford, UK, http://www.fmrib.ox.ac.uk/fsl).  All individual subject 
transformations and warp parameters from these steps were saved.  CBF maps 
were co-registered to the anatomical images using epi_reg (FSL).  Individual CBF 
maps were registered to standardised space by applying the saved transformations 
and warps using ANTs. 
 
To assess insulin induced changes in global perfusion whole brain median grey 
matter (GM) CBF values, constrained to a standardised GM mask, were extracted 
from the processed CBF maps and compared using a paired t-test, judged to p < 
0.05 significance.  In order to ascertain group level changes in CBF we extracted 
median values from regions of interest (ROI) for each participant and condition.  
Regions known to possess insulin receptors were created into masks using the FWU 
pick atlas toolbox, with the AAL human atlas in SPM (SPM-12, Wellcome Trust 
Centre for Neuroimaging, University College London, UK, 
http://www.fil.ion.ucl.ac.uk/spm).  These regions where the left and right 
hippocampus and amygdala, respectively, (see figure 3) which were picked due to 
the presence of insulin receptors within these regions [26].  
 
2.4.4 Blood insulin, C-peptide and glucose concentration 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
Venous blood was collected prior to administration of either insulin or saline (pre-
dose) and immediately after the scanning protocol was completed (post-scan).  The 
duration between these two time points was approximately two hours.  Blood was 
collected by venepuncture from the cubital vein.  Blood was collected into plasma 
and serum separating vacutainers (two vacutainers in total).  These samples were 
centrifuged, and plasma and serum was extracted into aliquots for analysis.   
Biochemical analysis was performed for serum insulin and C-peptide (Siemens 
Healthcare Centaur Assays) and plasma glucose (Siemens Healthcare AVIDA).  
 
2.5 Data analysis 
Data for the nasal spray characterisation is presented as mean ± sd,  Statistical 
analysis was conducted using R statistical analysis software (Rstudio – version 
1.1453, Boston, MA, http://www.rstudio.org/).  As mentioned in the relevant sections 
above unpaired t-tests were performed between pump configurations to compare 
droplet size distributions, plume geometry and spray pattern analysis.  For the spray 
pattern analysis a Mann Whitney Test for unpaired samples was used for spray 
pattern measures at 60 mm  P values were judged to p < 0.05 and p < 0.01 
significance. For nasal cast deposition analysis a two way analysis of variance 
(ANOVA) model was constructed with a Bonferroni post hoc test and p values < 0.05 
were considered statistically significant.  
 
Plasma glucose, serum insulin and serum C-peptide measurements, pre dose and 
post scan, were tested for statistical differences using paired t-tests for each 
condition.  P values were judged to p < 0.05 significance.  For the MRI data, the 
extracted CBF values were statistically compared to look for treatment related 
differences (insulin vs saline placebo) in regional CBF using a paired t-test for each 
ROI, a p value of 0.05 was used as a threshold of significance for this analysis.  
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3. Results 
The three devices for nasal delivery of insulin solution were evaluated in terms of the 
emitted aerosol spray characteristics (dosimetry, droplet size, spray geometry, in 
vitro deposition), after which the device with the optimal deposition pattern was 
evaluated for induction of changes in regional cerebral blood flow in humans in 
response to intranasal administration of insulin. 
 
3.1 Spray droplet size 
The pump configurations and are illustrated in Figure 2.  Spray droplet size was 
evaluated for each pump data (Figure 2; table 1).  No significant differences in Dv10, 
50 or 90 were seen between 3959 or 4290 at 30 mm.  Significant differences were 
seen between 3959 and Prototype at 30 mm: mean difference = -5.9 µm, -22.9 µm 
and -50.8 µm, for Dv10 (p<0.05), Dv50 (p<0.05) and Dv90 (p<0.001), respectively.  
Significant differences were also seen between 4290 and Prototype at 30 mm: mean 
difference =-7.8 µm, -26.2 µm and -55.6 µm, for Dv10 (p<0.001), Dv50 (p<0.001) 
and Dv90 (p<0.001), respectively.  Furthermore, droplet size distribution at 60 mm 
differed between all the devices with the 4290 producing the smallest and the 
Prototype producing the largest droplets.  Potential respirable fractions (droplets < 10 
µm) for all pump configurations were very low; < 1.5% for all devices.   
 
3.2 Plume Geometry and Spray Pattern 
Representative images of the spray profile for each device are displayed in Figure 4, 
along with average plume angle and width parameters.  No significant differences 
were seen between the 3959 and 4290 devices for either plume angle or width.  
Significant differences were seen for plume angle and width between the 3959 
device (mean ± sd = 37.8 ± 3.9° and 41.3 ± 4.6 mm, respectively) and the Prototype 
device (mean ± sd = 27.5 ± 7.8° and 29.9 ± 8.9 mm, respectively).  Similarly, 
significant differences between the 4290 device (mean ± sd = 42.7 ± 3.7° and 47.3 ± 
4.6 mm, respectively) and the Prototype device were observed. 
 
Spray pattern images were analysed and measurements of the spray area and spray 
ovality are presented in Figure 4C and D.  Spray pattern measurements for the 
devices at 30 mm and 60 mm were compared using the Mann Whitney test for 
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unpaired data (n=4).  There was no significant difference between the spray area 
produced by the devices at either height.  The 4290 configuration produced higher 
ovality scores (more elliptical) compared to both the 3959 and the Prototype at 60 
mm, but the differences were small.  
 
3.3 In vitro deposition 
A nasal cast (Figure 5a) was used to evaluate the deposition of insulin from the three 
nasal pump-actuator configurations.  Insulin solution was recovered from almost all 
of the nasal cast sections (Figure 5b), with slightly different deposition profiles for 
each of the three nasal pump-actuator combinations.  The highest deposition was in 
the nasal vestibules for all configurations with significant difference in the proportion 
of dose deposited between 3959 and the Prototype (mean ± sd = 47.1 ± 2.8% vs 
78.9 ± 3.7%, p<0.001).  Insulin deposition in the middle / upper turbinates section of 
the cast, i.e. the section where the target olfactory epithelium is located, was 17.9 ± 
7.1%, 16.7 ± 6.1% and 4.7 ± 4.2% for the 3959, 4290 and Prototype, respectively.  
Less than 0.1% of the formulation from all nasal pump-actuator configurations 
passed through the nasal cast model to constitute an inhalable fraction to the lungs. 
 
3.4 Magnetic Resonance Imaging  
The 3959 actuator with SP270+ pump was used for the magnetic resonance imaging 
component of this work.  All subjects were compliant with the drug administration 
protocol and handled the 3959 configured nasal spray device competently.  No 
adverse effects were reported for either intranasal saline or insulin formulations.  
One subject was excluded from the analysis for failure to comply with the fasting 
protocol (detected on the basis of pre-dose administration ‘fasting’ blood insulin 
concentration greater than 50 mIU/L) and therefore the MRI analysis and hunger 
rating analysis was conducted on the fifteen remaining participants.  Due to issues 
with blood sampling for a further individual subject, blood analysis was only 
conducted on fourteen subjects.  
 
There were no significant changes in plasma glucose, serum insulin or serum C-
peptide at either pre-dose or post scan time points after insulin treatment compared 
to saline control (table 2).  In some participants treated with insulin a small decrease 
in blood glucose was detected in combination with a small rise in insulin, however 
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this effect was not statistically significant between insulin and saline administration 
when analysed for whole study.  For both insulin and control arms of the study there 
was a significant effect of time on serum C-peptide concentration which significantly 
decreased between the pre-dose and post scan measurement times (p = 0.015 and 
p = 0.013, for saline placebo and insulin, respectively).  
 
3.5 Central Effects of Intranasal Insulin 
Paired t-tests from CBF values extracted from the global grey matter revealed no 
difference between conditions (table 3).  For regional CBF assessment both the left 
and right amygdala structures revealed significant CBF decreases in response to 
intranasal insulin (p= 0.037 and 0.027, respectively).  Slight CBF decreases in 
response to insulin were detected from the left and right hippocampal ROIs but were 
not statistically significant (mean decrease = 2.14 ml/100 g/min and 2.38 ml/100 
g/min, p = 0.32 and p = 0.24, for saline placebo and insulin, respectively).  
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4. Discussion 
 
This was a comparative study that analysed the insulin solution spray characteristics 
of three commercial, nasal pump delivery device configurations.  This study has 
determined pump performance in terms of the nasal deposition and used fMRI to 
study the CNS effects of intranasal insulin in human volunteers.  A priori criteria to 
select the best pump were droplet size between 20 µm and 50 µm contained in a 
narrow plume between 30° and 45° [12-14].  
 
The nasal cast data showed obvious deposition differences between the different 
pump configurations.  All pumps delivered high deposition in the nasal vestibule and 
at the expense of deep penetration into the nasal cavity.  This is a typical deposition 
profile of a normal liquid nasal spray [27].  However, the 3959 and SP270+ 
configuration showed the least nasal vestibule deposition and the highest deposition 
within the lower, middle and upper turbinates in comparison to the two other tested 
pumps with a more evenly distributed deposition across the nasal cast regions.  As 
inferred from the droplet size data, the prototype device, which had considerably 
larger droplets, deposited mainly at in the nasal vestibule.  The high inertia carried by 
these larger droplets favours increased impaction in anterior regions and reduced 
ability for the plume to navigate the convoluted anatomy of the nasal cast and cavity.  
The 4290 with SP270+ configuration showed similar characteristics to the 3959 but 
differed significantly with regards to nasal cast deposition at the level of the nasal 
vestibule and lower turbinate.  This deposition profile may be related to the plume 
angle associated with this pump resulting in more deposition in anterior regions of 
the nasal cast model.   
 
These data indicate that the SP270+ with both 3959 and 4290 actuators produced 
well developed plumes with characteristics that met the a priori criteria.  A narrow 
plume with larger droplets, such as that demonstrated by the Prototype, acts like a 
jet/hose rather than a mist which is sub-optimal for upper nasal cavity deposition, 
making it less efficient for nose-to-brain delivery of insulin.  The SP270+ with 3959 
and 4290 actuators produced sprays with favourable characteristics for the intended 
use.  Droplet size distributions at 30 mm were equivalent for both pumps with over 
50% in the target 20-50 µm range.  The measured plume angle and ovality at 30 mm 
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was similar for both devices, producing sprays in the range of 30-45°.  As the plumes 
were no different at 30 mm, a distance more anatomically relevant than 60 mm, 
device manoeuvrability and ease of use were used as supplementary criteria to 
select a device for use in the human study.  The 3959 actuator was considered to 
have ergonomic advantages, due to the finger grips and shape providing an easier 
handling during actuation which may result in more reproducible use by human 
volunteers in the imaging study.  Thus, the SP270+ pump with the 3959 actuator was 
selected for use in the MRI study of the central effects of nose-brain insulin in 
humans.  It is intriguing to speculate whether the differences in the performance of 
the nasal delivery devices types would have manifested in measurable differences in 
response to delivery of insulin to the brain, but this was unfortunately beyond the 
scope of this investigation. 
 
All subjects used the nasal spray device competently and had no problems following 
the administration protocol.  When insulin was administered, there were small 
increases in serum insulin concentration in some participants which has been 
reported previously with this dose and is an effect of overspill into the peripheral 
circulation [11].  However, serum insulin concentrations were not significantly 
different when participants were administered insulin compared to saline when the 
study was analysed collectively.  There was a small reduction in plasma glucose 
concentration associated with the participants for whom insulin levels were raised, 
although this too was not statistically significant as an effect of treatment.  The 
decrease in C-peptide over the duration of the study was observed for insulin- and 
saline-treated participants and represents a normal decrease in c-peptide release 
during periods of fasting.  As serum insulin, glucose and c-peptide varied minimally 
in response to treatment, and differences were statistically insignificantly overall, it 
was considered that the changes in CBF were responses to insulin transported to 
the CNS via nose to brain delivery rather than the result of secondary insulin 
transportation to the CNS after systemic absorption.  
 
The functional relationship between neural activity and CBF permitted the use of 
ASL MRI to explore brain function using CBF as a surrogate measure and was used 
to assess the central effects of intranasal insulin [28].  ASL works by magnetically 
tagging or labelling the hydrogen nuclei of water molecules within the major feeding 
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arteries of the brain (carotid arteries), waiting for these tagged molecules to reach 
the capillary bed of the brain tissue and then acquiring an image.  This is called a 
tagged image.  A second image is acquired with identical parameters, but in this 
case with no labelling of arterial blood, known as a control image.  The two images 
are subtracted from each other to remove the static tissue signal and what remains 
is an image with signal related entirely to the volume of labelled water molecules that 
have perfused into the tissue to produce a perfusion weighted image [29, 30].  From 
these perfusion weighted images, a map of CBF in physiological units can be 
calculated using a suitable model [31].  These maps were used to study differences 
in regional CBF within this study. 
We report no change in global CBF in response to insulin, an observation witnessed 
previously [32].  Despite the exclusion of one of the participants from the analysis we 
had sufficient statistical power to detect a significant treatment group level decrease 
in CBF in response to 160 IU insulin compared to saline placebo in the left and right 
amygdala. From pre-clinical and in vitro literature the central nucleus of the 
amygdala expresses an abundance of insulin receptors [33].  Binding of insulin to 
these receptors has been shown to selectively increase both the amplitude and 
frequency of spontaneous inhibitory postsynaptic currents [33].  The consequent 
reduction in oxygen demand in the amygdala leads to lower cerebral perfusion.  
Previous reports have shown decreases in CBF associated with 160 IU intranasal 
insulin dose in the hypothalamus [11], but no study has reported changes within the 
amygdala, a region that is involved in food intake and appetite control [34].  
Interestingly, direct administration of insulin to the amygdala in rats has previously 
shown an acute reduction in food intake coupled with reduced appetite [35].  
Previous reports have identified an hunger or appetite blunting effect following 
intranasal insulin administration [36, 37] and the results reported here may offer a 
possible explanation for these anorectic effects.  
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5. Conclusion 
 
As a proof of concept we have, through the use of functional MRI, shown that a 
commercial nasal pump can be used to deliver insulin within the nasal cavity to 
produce a pharmacological effect in the brain of healthy human volunteers.  This is 
the first time that a nasal pump with human insulin has been characterised fully in 
terms of aerosol delivery and used in a human magnetic resonance imaging study.  
Thus, our results provide evidence of successful nose-to-brain delivery of insulin to 
engage brain insulin receptors resulting in changes in cerebral perfusion within the 
amygdala. 
 
We have shown that a commercial nasal pump with human insulin can be used to 
induce measurable effects within the central nervous system.  This constitutes a 
simple, cost effective means of administration for centrally acting drugs for use in 
neuropharmacological research, biomedical applications or therapeutic interventions.  
The delivery device used for this purpose was not optimised and the insulin solution 
was not modified to target olfactory delivery.  We recommend thorough 
characterisation of the nasal delivery device and qualitative/quantitative assessment 
of the administered dose is reported in all studies of nose to brain delivery so that 
responses can be evaluated with respect to posology and comparison between 
studies is facilitated.   
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Table 1  Droplet size measurements obtained from each pump measured at 30 mm 
and 60 mm from the tip of the actuator. Data is mean ± sd (n=5) 
Droplet Size in µm: 30 mm Distance 
 
3959 4290 Prototype 
Dv10 18.03 ± 2.95 23.98 ± 3.86 23.98 ± 3.86 
Dv50 37.20 ± 2.20 60.06 ± 16.27 60.06 ± 16.27 
Dv90 76.34 ± 3.79 71.52 ± 13.34 127.14 ± 29.77 
Droplet Size in µm: 60 mm Distance 
 
3959 4290 Prototype 
Dv10 21.80 ± 1.58 19.40 ± 4.08 28.72 ± 2.87 
Dv50 39.65 ± 0.10 34.95 ± 1.33 56.50 ± 11.32 
Dv90 69.56 ± 1.69 61.02 ± 3.35 111.67 ± 31.28 
The measured droplet size differed between pumps and these statistical comparisons are 
represented in Figure 2. 
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Table 2  Measurements of plasma glucose, serum insulin, C-peptide, pre-dose and 
post-scan, following intranasal administration of insulin 160 IU/mL and saline 0.9% 
w/v (control). Data represent mean ± sd, n=14 (one participant did not have complete 
blood data), and show significant p values (*) calculated from paired t-tests (p < 
0.05).  
 
Peripheral Blood Analysis 
 
Saline Insulin 
 
Pre Post Pre Post 
Plasma Glucose 
(mmol/L) 
4.99 ± 0.32 4.95 ± 0.31 4.99 ± 0.38 4.82 ± 0.41 
Serum Insulin 
(mIU/L) 
6.99 ± 3.85 6.64 ± 4.71 9.76 ± 8.27 16.79 ± 13.48 
Serum C-peptide 
(pmol/L) 
496.57 ± 166.25  434.50 ± 155.40 * 487.29 ± 170.35  338.57 ± 144.98 * 
                      * p < 0.05, significant decrease in post scan measurements  
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Table 3. Global and regional cerebral blood flow values extracted from the grey 
matter and amygdala and hippocampus, respectively for both saline and insulin 
conditions. CBF values are reported as mean ± sd and were compared across 
conditions using paired t-tests and significance was defined as p < 0.05 *, n=15.   
Global and Regional Cerebral Blood Flow (ml/ 100 g/ min) 
 
Saline Insulin 
Grey matter 59.19 ± 5.83 59.60 ± 4.98 
Amygdala 
    
Left 46.68 ± 5.72  42.72 ± 6.97 * 
Right 44.85 ± 6.07  40.80 ± 6.57 * 
Hippocampus 
    
Left 45.98 ± 4.49 43.84 ± 5.75 
Right 45.66 ± 4.17 43.27 ± 5.83 
* p < 0.05, significant insulin related decreases compared to saline 
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Figure 1.  Schematic drawings and anatomical MRI images of the olfactory bulb and 
nerve fibres within the nasal cavity and central nervous system. A) schematic 
diagram of the olfactory bulb and olfactory nerve fibres that breach the cribriform 
plate (circled in red). B) An axial T2 weighted image from a representative subject 
showing the olfactory bulb (red arrows). C) Coronal T2 weighted images show the 
intricacy of the nasal cavity and also the olfactory bulbs (red arrows). D) Sagittal T1 
weighted image of the same representative subject showing the olfactory bulb lying 
superior to the cribriform plate (red arrow). 
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Figure 2.  Nasal spray devices and aerosol particle size distributions. (A) The 
SP270+ pump with 3959 or 4290 actuator and a prototype (PRO) pump; (B) droplet 
size at 30 mm, (C) droplet size at 60 mm.  Data represent mean ± sd (n=5). 
  
B C 
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Figure 3.  Amygdala and hippocampal region of interest masks. The amygdala and 
hippocampus were used as regions of interest to explore effects of intranasal insulin 
on perfusion, overlaid onto a standard anatomical brain in MNI space.  
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Figure 4.  Aerosol geometry of SP270+ pump with 3959 or 4290 actuator and a 
prototype (PRO) pump. (A) plume angle and width at 60 mm, (B) representative 
images of a stable phase plume. Data represent mean ± sd (n=5); (C) plume area 
(mm2) and (D) ovality measurements at 30 and 60 mm. The red dashed line 
represents the line of absolute ovality =1.  Data represent mean ± sd (n=5 for 
3959,4290 and n=4 for prototype). *p<0.05 and **p<0.01. 
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Figure 5.  In vitro deposition in the upper turbinate for nose to brain transport: (a) The 
nasal cast sections (from top left: nostrils, nasal vestibule, lower turbinates; from 
bottom left: middle and upper turbinates, nasopharynx), (b) deposition fractions in 
the target area of nostrils, nasal vestibules, lower turbinates, middle and upper 
turbinates, nasopharynx for insulin aerosols from SP270+ pump with 3959 or 4290 
actuator and a prototype (PRO) pump, respectively. Data represent mean ± sd (n=9). 
*p<0.05, **p<0.01, ***p<0.001 
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